Aging in the canine and feline brain

Veterinary Clinics of North America - Small Animal Practice

Volumn 44, Issue 6, 2014, Pages 1113-1129

  Vite, Charles H ^a   Head, Elizabeth ^b  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cat; Cognitive dysfunction; Dog; Neuron loss; Tau; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

AGING; AUTOPHAGY; BRAIN ATROPHY; BRAIN DISEASE; BRAIN NERVE CELL; CAT; CELL LOSS; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOG; LYSOSOME STORAGE DISEASE; NEUROBIOLOGY; NEUROPATHOLOGY; NIEMANN PICK DISEASE; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; SPECIES COMPARISON; VASCULAR AMYLOIDOSIS; ANIMAL; CAT DISEASE; DOG DISEASE; PATHOLOGY; VETERINARY;

AGING; ANIMALS; BRAIN DISEASES; CAT DISEASES; CATS; DOG DISEASES; DOGS;

EID: 84908507281     PISSN: 01955616     EISSN: 18781306     Source Type: Journal    
DOI: 10.1016/j.cvsm.2014.07.008     Document Type: Review

References (140)

1. Greer K.A., Canterberry S.C., Murphy K.E. Statistical analysis regarding the effects of height and weight on life span of the domestic dog. Res Vet Sci 2007, 82(2):208-214.
2. Galis F., Van der Sluijs I., Van Dooren T.J., et al. Do large dogs die young?. JExp Zool B Mol Dev Evol 2007, 308(2):119-126.
3. Patronek G.J., Waters D.J., Glickman L.T. Comparative longevity of pet dogs and humans: implications for gerontology research. JGerontol A Biol Sci Med Sci 1997, 52(3):B171-B178.
4. Lowseth L.A., Gillett N.A., Gerlach R.F., et al. The effects of aging on hematology and serum chemistry values in the beagle dog. Vet Clin Pathol 1990, 19(1):13-19.
5. Cotman C.W., Head E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. JAlzheimers Dis 2008, 15(4):685-707.
6. Landsberg G., Araujo J.A. Behavior problems in geriatric pets. Vet Clin North Am Small Anim Pract 2005, 35(3):675-698.
7. Landsberg G., Ruehl W. Geriatric behavioral problems. Vet Clin North Am Small Anim Pract 1997, 27(6):1537-1559.
8. Vandevelde M., Higgins R.J., Oevermann A. Veterinary neuropathology: essentials of theory and practice 2012, Wiley-Blackwell, West Sussex (United Kingdom).
9. Su M.Y., Head E., Brooks W.M., et al. MR imaging of anatomic and vascular characteristics in a canine model of human aging. Neurobiol Aging 1998, 19(5):479-485.
10. Kimotsuki T., Nagaoka T., Yasuda M., et al. Changes of magnetic resonance imaging on the brain in beagle dogs with aging. JVet Med Sci 2005, 67(10):961-967.
11. Gonzalez-Soriano J., Marin Garcia P., Contreras-Rodriguez J., et al. Age-related changes in the ventricular system of the dog brain. Ann Anat 2001, 183(3):283-291.
12. Tapp P.D., Siwak C.T., Gao F.Q., et al. Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. JNeurosci 2004, 24(38):8205-8213.
13. Hasegawa D., Yayoshi N., Fujita Y., et al. Measurement of interthalamic adhesion thickness as a criteria for brain atrophy in dogs with and without cognitive dysfunction (dementia). Vet Radiol Ultrasound 2005, 46(6):452-457.
14. Grossman R.I., Yousem D.M. Neuroradiology: the requisites 2003, Mosby, Philadelphia.
15. Simic G., Kostovic I., Winblad B., et al. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. JComp Neurol 1997, 379(4):482-494.
16. West M.J. Regionally specific loss of neurons in the aging human hippocampus. Neurobiol Aging 1993, 14:287-293.
17. West M.J., Kawas C.H., Martin L.J., et al. The CA1 region of the human hippocampus is a hot spot in Alzheimer's disease. Ann N Y Acad Sci 2000, 908:255-259.
18. Bobinski M., Wegiel J., Tarnawski M., et al. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. JNeuropathol Exp Neurol 1997, 56(4):414-420.
19. Siwak-Tapp C.T., Head E., Muggenburg B.A., et al. Region specific neuron loss in the aged canine hippocampus is reduced by enrichment. Neurobiol Aging 2008, 29(1):39-50.
20. Pugliese M., Gangitano C., Ceccariglia S., et al. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes. Brain Res 2007, 1139:85-94.
21. Insua D., Suarez M.L., Santamarina G., et al. Dogs with canine counterpart of Alzheimer's disease lose noradrenergic neurons. Neurobiol Aging 2008, 31(4):625-635.
22. Dringenberg H.C. Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 2000, 115(2):235-249.
23. Grudzien A., Shaw P., Weintraub S., et al. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 2007, 28(3):327-335.
24. Siwak-Tapp C.T., Head E., Muggenburg B.A., et al. Neurogenesis decreases withage in the canine hippocampus and correlates with cognitive function. Neurobiol Learn Mem 2007, 88(2):249-259.
25. Pekcec A., Baumgartner W., Bankstahl J.P., et al. Effect of aging on neurogenesis in the canine brain. Aging Cell 2008, 7(3):368-374.
26. Cummings B.J., Head E., Ruehl W., et al. The canine as an animal model of human aging and dementia. Neurobiol Aging 1996, 17(2):259-268.
27. Mirra S.S., Heyman A., McKeel D., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41(4):479-486.
28. Murphy M.P., LeVine H. Alzheimer's disease and the amyloid-beta peptide. JAlzheimers Dis 2010, 19(1):311-323.
29. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. JBiol Chem 1996, 271:18295-18298.
30. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81(2):741-766.
31. Johnstone E.M., Chaney M.O., Norris F.H., et al. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res 1991, 10(4):299-305.
32. Selkoe D.J., Bell D.S., Podlisny M.B., et al. Conservation of brain amyloid proteins inagedmammals and humans with Alzheimer's disease. Science 1987, 235(4791):873-877.
33. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. JAlzheimers Dis 2006, 9(3 Suppl):151-153.
34. Wisniewski H.M., Wegiel J., Morys J., et al. Aged dogs: an animal model to study beta-protein amyloidogenesis. Alzheimer's disease. Epidemiology, neuropathology, neurochemistry and clinics 1990, 151-167. Springer-Verlag, New York. K. Maurer, P. Riederer, H. Beckman (Eds.).
35. Cummings B.J., Su J.H., Cotman C.W., et al. Beta-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol Aging 1993, 14(6):547-560.
36. Giaccone G., Verga L., Finazzi M., et al. Cerebral preamyloid deposits and congophilic angiopathy in aged dogs. Neurosci Lett 1990, 114:178-183.
37. Morys J., Narkiewicz O., Maciejewska B., et al. Amyloid deposits and loss of neurones in the claustrum of the aged dog. Neuroreport 1994, 5(14):1825-1828.
38. Okuda R., Uchida K., Tateyama S., et al. The distribution of amyloid beta precursor protein in canine brain. Acta Neuropathol 1994, 87:161-167.
39. Russell M.J., White R., Patel E., et al. Familial influence on plaque formation in the beagle brain. Neuroreport 1992, 3(12):1093-1096.
40. Uchida K., Tani Y., Uetsuka K., et al. Immunohistochemical studies on canine cerebral amyloid angiopathy and senile plaques. JVet Med Sci 1992, 54(4):659-667.
41. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82(4):239-259.
42. Braak H., Braak E., Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993, 33:403-408.
43. Head E., McCleary R., Hahn F.F., et al. Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging 2000, 21(1):89-96.
44. Ishihara T., Gondo T., Takahashi M., et al. Immunohistochemical and immunoelectron microscopical characterization of cerebrovascular and senile plaque amyloid in aged dogs' brains. Brain Res 1991, 548:196-205.
45. Thal D.R., Rub U., Orantes M., et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58(12):1791-1800.
46. Wisniewski H.M., Johnson A.B., Raine C.S., et al. Senile plaques and cerebral amyloidosis in aged dogs. Lab Invest 1970, 23:287-296.
47. Colle M.A., Hauw J.J., Crespeau F., et al. Vascular and parenchymal Ab deposition in the aging dog: correlation with behavior. Neurobiol Aging 2000, 21:695-704.
48. Cummings B.J., Head E., Afagh A.J., et al. Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem 1996, 66(1):11-23.
49. Head E., Callahan H., Muggenburg B.A., et al. Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging 1998, 19(5):415-425.
50. Rofina J.E., van Ederen A.M., Toussaint M.J., et al. Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain Res 2006, 1069(1):216-226.
51. Rofina J., van Andel I., van Ederen A.M., et al. Canine counterpart of senile dementia of the Alzheimer type: amyloid plaques near capillaries but lack of spatial relationship with activated microglia and macrophages. Amyloid 2003, 10(2):86-96.
52. Rofina J.E., Singh K., Skoumalova-Vesela A., et al. Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid 2004, 11(2):90-100.
53. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192(1):106-113.
54. Tomic J.L., Pensalfini A., Head E., et al. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009, 35(3):352-358.
55. Lacor P.N., Buniel M.C., Chang L., et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. JNeurosci 2004, 24(45):10191-10200.
56. Pop V., Head E., Berchtold N.C., et al. Aβ aggregation profiles and shifts in APP processing favor amyloidogenesis in canines. Neurobiol Aging 2012, 33(1):108-120.
57. Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 2005, 110(4):345-359.
58. Attems J., Jellinger K.A., Lintner F. Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 2005, 110(3):222-231.
59. Herzig M.C., Van Nostrand W.E., Jucker M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol 2006, 16(1):40-54.
60. Prior R., D'Urso D., Frank R., et al. Loss of vessel wall viability in cerebral amyloid angiopathy. Neuroreport 1996, 7:562-564.
61. Uchida K., Nakayama H., Goto N. Pathological studies on cerebral amyloid angiopathy, senile plaques and amyloid deposition in visceral organs in aged dogs. JVet Med Sci 1991, 53(6):1037-1042.
62. Garosi L., McConnell J.F., Platt S.R., et al. Clinical and topographic magnetic resonance characteristics of suspected brain infarction in 40 dogs. JVet Intern Med 2006, 20(2):311-321.
63. Goncalves R., Carrera I., Garosi L., et al. Clinical and topographic magnetic resonance imaging characteristics of suspected thalamic infarcts in 16 dogs. Vet J 2011, 188(1):39-43.
64. Su M.Y., Tapp P.D., Vu L., et al. Alongitudinal study of brain morphometrics using serial magnetic resonance imaging analysis in a canine model of aging. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(3):389-397.
65. Liu S., Hu W.X., Zu Q.Q., et al. Anovel embolic stroke model resembling lacunar infarction following proximal middle cerebral artery occlusion in beagle dogs. JNeurosci Methods 2012, 209(1):90-96.
66. Head E., Moffat K., Das P., et al. Beta-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol Aging 2005, 26(5):749-763.
67. Yu C.H., Song G.S., Yhee J.Y., et al. Histopathological and immunohistochemical comparison of the brain of human patients with Alzheimer's disease and the brain of aged dogs with cognitive dysfunction. JComp Pathol 2011, 145(1):45-58.
68. Head E., Liu J., Hagen T.M., et al. Oxidative damage increases with age in a canine model of human brain aging. JNeurochem 2002, 82:375-381.
69. Skoumalova A., Rofina J., Schwippelova Z., et al. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp Gerontol 2003, 38:711-719.
70. Kiatipattanasakul W., Nakamura S., Kuroki K., et al. Immunohistochemical detection of anti-oxidative stress enzymes in the dog brain. Neuropathology 1997, 17:307-312.
71. Opii W.O., Joshi G., Head E., et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging 2008, 29(1):51-70.
72. Hwang I.K., Yoon Y.S., Yoo K.Y., et al. Differences in lipid peroxidation and Cu,Zn-superoxide dismutase in the hippocampal CA1 region between adult and aged dogs. JVet Med Sci 2008, 70(3):273-277.
73. Papaioannou N., Tooten P.C., van Ederen A.M., et al. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid 2001, 8:11-21.
74. Shigenaga M.K., Hagen T.M., Ames B.N. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 1994, 91:10771-10778.
75. Head E., Nukala V.N., Fenoglio K.A., et al. Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging. Exp Neurol 2009, 220(1):171-176.
76. Kuruppu D.K., Matthews B.R. Young-onset dementia. Semin Neurol 2013, 33(4):365-385.
77. Swain G.P., Prociuk M., Bagel J.H., et al. Adeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain. Gene Ther 2014, 21(1):28-36.
78. Ellinwood N.M., Vite C.H., Haskins M.E. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. JGene Med 2004, 6(5):481-506.
79. Raz N., Rodrigue K.M., Haacke E.M. Brain aging and its modifiers: insights from invivo neuromorphometry and susceptibility weighted imaging. Ann N Y Acad Sci 2007, 1097:84-93.
80. Dolisca S.B., Mehta M., Pearce D.A., et al. Batten disease: clinical aspects, molecular mechanisms, translational science, and future directions. JChild Neurol 2013, 28(9):1074-1100.
81. Hofmann S.L., Peltonen L. The Neuronal Ceroid Lipofuscinoses. OMMBID - The Online Metabolic and Molecular Bases of Inherited Diseases. 2014, McGraw-Hill, New York, NY, Accessed August 20, 2014. http://ommbid.mhmedical.com/content.aspx?bookid=474%26Sectionid=45374157, D. Valle, A.L. Beaudet, B. Vogelstein (Eds.).
82. Jolly R.D. Comparative biology of the neuronal ceroid-lipofuscinoses (NCL): anoverview. Am J Med Genet 1995, 57(2):307-311.
83. Jolly R.D., Brown S., Das A.M., et al. Mitochondrial dysfunction in the neuronal ceroid-lipofuscinoses (Batten disease). Neurochem Int 2002, 40(6):565-571.
84. Sanders D.N., Kanazono S., Wininger F.A., et al. Areversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis. Genes Brain Behav 2011, 10(7):798-804.
85. Vuillemenot B.R., Katz M.L., Coates J.R., et al. Intrathecal tripeptidyl-peptidase 1reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2011, 104(3):325-337.
86. Shapiro E., Guler O.E., Rudser K., et al. An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT). Mol Genet Metab 2012, 107(1-2):116-121.
87. Vite C.H., Nestrasil I., Mlikotic A., et al. Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I. Comp Med 2013, 63(2):163-173.
88. Pelissier C., Roudier M., Boller F. Factorial validation of the severe impairment battery for patients with Alzheimer's disease. A pilot study. Dement Geriatr Cogn Disord 2002, 13(2):95-100.
89. Ferris S., Karantzoulis S., Somogyi M., et al. Rivastigmine in moderately severe-to-severe Alzheimer's disease: severe impairment battery factor analysis. Alzheimers Res Ther 2013, 5(6):63.
90. Dierenfeld A.D., McEntee M.F., Vogler C.A., et al. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med 2010, 2(60):60ra89.
91. Chen A., Vogler C., McEntee M., et al. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase. APMIS 2011, 119(8):513-521.
92. Gunn-Moore D., Moffat K., Christie L.A., et al. Cognitive dysfunction and the neurobiology of ageing in cats. JSmall Anim Pract 2007, 48(10):546-553.
93. Landsberg G.M., Denenberg S., Araujo J.A. Cognitive dysfunction in cats: a syndrome we used to dismiss as 'old age'. JFeline Med Surg 2010, 12(11):837-848.
94. Levine M.S., Lloyd R.L., Fisher R.S., et al. Sensory, motor and cognitive alterations in aged cats. Neurobiol Aging 1987, 8:253-263.
95. Levine M.S., Adinolfi A.M., Fisher R.S., et al. Quantitative morphology of medium-sized caudate spiny neurons in aged cats. Neurobiol Aging 1986, 7(4):277-286.
96. Levine M.S., Adinolfi A.M., Fisher R.S., et al. Ultrastructural alterations in caudate nucleus in aged cats. Brain Res 1988, 440(2):267-279.
97. Levine M.S. Neurophysiological and morphological alterations in caudate neurons in aged cats. Ann N Y Acad Sci 1988, 515:314-328.
98. Zhang J.H., Sampogna S., Morales F.R., et al. Age-related changes in cholinergic neurons in the laterodorsal and the pedunculo-pontine tegmental nuclei of cats: a combined light and electron microscopic study. Brain Res 2005, 1052(1):47-55.
99. Cummings B.J., Satou T., Head E., et al. Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Neurobiol Aging 1996, 17(4):653-659.
100. Gunn-Moore D.A., McVee J., Bradshaw J.M., et al. Ageing changes in cat brains demonstrated by beta-amyloid and AT8-immunoreactive phosphorylated tau deposits. JFeline Med Surg 2006, 8(4):234-242.
101. Nakamura S., Nakayama H., Kiatipattanasakul W., et al. Senile plaques in very aged cats. Acta Neuropathol 1996, 91:437-439.
102. Brellou G., Vlemmas I., Lekkas S., et al. Immunohistochemical investigation of amyloid beta-protein (Abeta) in the brain of aged cats. Histol Histopathol 2005, 20(3):725-731.
103. Takeuchi Y., Uetsuka K., Murayama M., et al. Complementary distributions of amyloid-beta and neprilysin in the brains of dogs and cats. Vet Pathol 2008, 45(4):455-466.
104. Chambers J.K., Mutsuga M., Uchida K., et al. Characterization of AbetapN3 deposition in the brains of dogs of various ages and other animal species. Amyloid 2011, 18(2):63-71.
105. Goedert M., Jakes R., Crowther R.A., et al. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci USA 1993, 90:5066-5070.
106. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995, 16(3):271-284.
107. Janke C., Beck M., Stahl T., et al. Phylogenetic diversity of the expression of the microtubule-associated protein tau: implications for neurodegenerative disorders. Brain Res Mol Brain Res 1999, 68:119-128.
108. Braak H., Braak E., Strothjohann M. Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci Lett 1994, 171:1-4.
109. Kuroki K., Uchida K., Kiatipattanasakul W., et al. Immunohistochemical detection of tau proteins in various non-human animal brains. Neuropathology 1997, 17:174-180.
110. Walkley S.U., Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta 2004, 1685(1-3):48-62.
111. March P.A., Thrall M.A., Brown D.E., et al. GABAergic neuroaxonal dystrophy and other cytopathological alterations in feline Niemann-Pick disease type C. Acta Neuropathol 1997, 94(2):164-172.
112. Zervas M., Somers K.L., Thrall M.A., et al. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 2001, 11(16):1283-1287.
113. Somers K.L., Brown D.E., Fulton R., et al. Effects of dietary cholesterol restriction in a feline model of Niemann-Pick type C disease. JInherit Metab Dis 2001, 24(4):427-436.
114. Ward S., O'Donnell P., Fernandez S., et al. 2-Hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type Cdisease. Pediatr Res 2010, 68(1):52-56.
115. Ferris S., Cummings J., Christensen D., et al. Effects of donepezil 23 mg on severe impairment battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimers Res Ther 2013, 5(1):12.
116. Sarkar S., Carroll B., Buganim Y., et al. Impaired autophagy in the lipid-storage disorder Niemann-pick type C1 disease. Cell Rep 2013, 5(5):1302-1315.
117. Hara T., Nakamura K., Matsui M., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441(7095):885-889.
118. Keller J.N., Dimayuga E., Chen Q., et al. Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. Int J Biochem Cell Biol 2004, 36(12):2376-2391.
119. Komatsu M., Waguri S., Chiba T., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441(7095):880-884.
120. Kiselyov K., Jennigs J.J., Rbaibi Y., et al. Autophagy, mitochondria and cell death in lysosomal storage diseases. Autophagy 2007, 3(3):259-262.
121. Fu R., Yanjanin N.M., Bianconi S., et al. Oxidative stress in Niemann-Pick disease, type C. Mol Genet Metab 2010, 101(2-3):214-218.
122. Porter F.D., Scherrer D.E., Lanier M.H., et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med 2010, 2(56):56ra81.
123. Fu R., Yanjanin N.M., Elrick M.J., et al. Apolipoprotein E genotype and neurological disease onset in Niemann-Pick disease, type C1. Am J Med Genet A 2012, 158A(11):2775-2780.
124. Mattsson N., Olsson M., Gustavsson M.K., et al. Amyloid-beta metabolism in Niemann-Pick C disease models and patients. Metab Brain Dis 2012, 27(4):573-585.
125. Schedin S., Sindelar P.J., Pentchev P., et al. Peroxisomal impairment in Niemann-Pick type C disease. JBiol Chem 1997, 272(10):6245-6251.
126. Lloyd-Evans E., Morgan A.J., He X., et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 2008, 14(11):1247-1255.
127. Baudry M., Yao Y., Simmons D., et al. Postnatal development of inflammation in amurine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp Neurol 2003, 184(2):887-903.
128. Wu Y.P., Mizukami H., Matsuda J., et al. Apoptosis accompanied by up-regulation of TNF-alpha death pathway genes in the brain of Niemann-Pick type C disease. Mol Genet Metab 2005, 84(1):9-17.
129. van Echten-Deckert G., Walter J. Sphingolipids: critical players in Alzheimer's disease. Prog Lipid Res 2012, 51(4):378-393.
130. Houpt K.A., Beaver B. Behavioral problems of geriatric dogs and cats. Vet Clin North Am Small Anim Pract 1981, 11(4):643-652.
131. Mosier J.E. Effect of aging on body systems of the dog. Vet Clin North Am Small Anim Pract 1989, 19(1):1-12.
132. Chapman B.L., Voith V.L. Behavioral problems in old dogs: 26 cases (1984-1987). JAm Vet Med Assoc 1990, 196(6):944-946.
133. Ruehl W.W., Bruyette D.S., DePaoli A., et al. Canine cognitive dysfunction as amodel for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy. Prog Brain Res 1995, 106:217-225.
134. Landsberg G.M., Nichol J., Araujo J.A. Cognitive dysfunction syndrome: a disease of canine and feline brain aging. Vet Clin North Am Small Anim Pract 2012, 42(4):749-768. vii.
135. Bosch M.N., Pugliese M., Gimeno-Bayon J., et al. Dogs with cognitive dysfunction syndrome: a natural model of Alzheimer's disease. Curr Alzheimer Res 2012, 9(3):298-314.
136. Pugliese M., Geloso M.C., Carrasco J.L., et al. Canine cognitive deficit correlates with diffuse plaque maturation and S100beta (-) astrocytosis but not with insulin cerebrospinal fluid level. Acta Neuropathol 2006, 111(6):519-528.
137. Pugliese M., Mascort J., Mahy N., et al. Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits. Acta Neuropathol 2006, 112(2):175-183.
138. Head E., Cotman C.W., Zicker S.C., et al. The use of dietary antioxidants and mitochondrial co-factors to promote successful aging. Curr Top Nutraceutical Res 2005, 3(2):85-94.
139. Bosch M.N., Gimeno-Bayon J., Rodriguez M.J., et al. Rapid improvement of canine cognitive dysfunction with immunotherapy designed for Alzheimer's disease. Curr Alzheimer Res 2013, 10(5):482-493.
140. Gunn-Moore D.A. Cognitive dysfunction in cats: clinical assessment and management. Top Companion Anim Med 2011, 26(1):17-24.